U.S. Markets close in 2 hrs 25 mins
  • S&P 500

    4,579.76
    +4.97 (+0.11%)
     
  • Dow 30

    35,661.06
    -95.82 (-0.27%)
     
  • Nasdaq

    15,352.47
    +116.75 (+0.77%)
     
  • Russell 2000

    2,272.73
    -23.34 (-1.02%)
     
  • Gold

    1,797.60
    +4.20 (+0.23%)
     
  • EUR/USD

    1.1612
    +0.0009 (+0.0813%)
     
  • 10-Yr Bond

    1.5380
    -0.0810 (-5.00%)
     
  • Vix

    15.70
    -0.28 (-1.75%)
     
  • GBP/USD

    1.3752
    -0.0011 (-0.0825%)
     
  • USD/JPY

    113.7580
    -0.3710 (-0.3251%)
     
  • BTC-USD

    59,061.22
    -3,281.45 (-5.26%)
     
  • CMC Crypto 200

    1,420.28
    -54.05 (-3.67%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    29,098.24
    -7.76 (-0.03%)
     

Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI), effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index was launched in 1993 and is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. Companies in the NBI must meet eligibility requirements, including an average daily trading volume, minimum market capitalization, and other criteria. The index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit https://indexes.nasdaqomx.com/-Index/Overview/NBI.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-to-be-added-to-the-nasdaq-biotechnology-index-301195860.html

SOURCE Syndax Pharmaceuticals, Inc.